INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

Group 1 - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices [2] - Investors who purchased Ultragenyx securities during the Class Period have until April 6, 2026, to request appointment as Lead Plaintiff [2] - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate and securities class litigation [6] Group 2 - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4] - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to meet primary endpoints, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5]